US FDA slaps import alert on Dabur India's Dadra plant over data integrity, sanitation lapses
The US drug regulator has issued an import alert against Dabur India's Dadra and Nagar Haveli facility following an inspection that flagged falsified records, data integrity gaps and sanitation failures. Dabur says there is no material financial or operational hit and domestic products remain unaffected, with corrective action plans now submitted to the FDA.
US FDA issued an import alert on Dabur India's Dadra and Nagar Haveli plant after inspection flagged data integrity, falsified records, and sanitation lapses. Dabur says no financial or operational impact and domestic products are unaffected, while submitting corrective action plans.
Why this matters
Second US FDA action on Dabur's Union Territory manufacturing footprint, following the Import Alert 66-40 on its Silvassa drug unit over similar data integrity lapses, signaling deepening compliance scrutiny.
Retail-company signals steady at 2,700 over the last 90 days.